ERBB2 and breast cancer: We quantitated the surface target density of Ep-CAM and HER-2 on nine breast cancer cell lines, which were of different tumour source and differed with respect to the status of oestrogen receptor expression, HER-2 amplification and expression of FGF and TGFα (Table 1).